1. Home
  2. YQ vs CNSY Comparison

YQ vs CNSY Comparison

Compare YQ & CNSY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

YQ

17 Education & Technology Group Inc.

N/A

Current Price

$3.39

Market Cap

22.2M

Sector

Real Estate

ML Signal

N/A

Logo Cerenome Inc. Common Stock

CNSY

Cerenome Inc. Common Stock

N/A

Current Price

$2.14

Market Cap

20.6M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
YQ
CNSY
Founded
2012
N/A
Country
China
United States
Employees
N/A
N/A
Industry
Other Consumer Services
Medical/Dental Instruments
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
22.2M
20.6M
IPO Year
2020
2016

Fundamental Metrics

Financial Performance
Metric
YQ
CNSY
Price
$3.39
$2.14
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
70.8K
62.1K
Earning Date
06-09-2026
N/A
Dividend Yield
N/A
N/A
EPS Growth
N/A
87.61
EPS
N/A
N/A
Revenue
N/A
$5,213,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.68
$2.31
52 Week High
$6.45
$4.03

Technical Indicators

Market Signals
Indicator
YQ
CNSY
Relative Strength Index (RSI) 57.25 18.89
Support Level $3.28 N/A
Resistance Level $3.68 $3.05
Average True Range (ATR) 0.44 0.21
MACD 0.12 -0.06
Stochastic Oscillator 53.56 2.52

Price Performance

Historical Comparison
YQ
CNSY

About YQ 17 Education & Technology Group Inc.

17 Education & Technology Group Inc is engaged in providing education and education technology services in the People's Republic of China (PRC) with a focus on the Teaching and Learning SaaS offerings. It offers smart, in-school, teaching and learning SaaS offerings assist students, teachers, schoolmasters and educational authorities across China. It also offer other educational products and services that complement students' in-school learning. Geographically group operates in China.

About CNSY Cerenome Inc. Common Stock

Cerenome Inc is a CNS oncology company advancing an integrated platform that combines precision diagnostics, targeted therapeutics, and artificial intelligence to improve outcomes for patients with central nervous system cancers. The Company's CNSide Diagnostics platform supports the detection, molecular characterization, and longitudinal monitoring of CNS cancers through cerebrospinal fluid-based testing. Its therapeutic platform, REYOBIQ (rhenium Re186 obisbemeda), is being evaluated in clinical trials for leptomeningeal metastases, recurrent glioblastoma, and pediatric brain cancers. The data & artificial intelligence platform is designed to integrate diagnostic, molecular, imaging, and clinical data into actionable insights that support precision oncology and therapeutic innovation.

Share on Social Networks: